1IA
SGMO

1834 Investment Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

1834 Investment Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-700
Closed -$6K – 439
2019
Q4 		$6K Buy
+700
New +$6.44K ﹤0.01% 415

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

1834 Investment Advisors's SGMO Position: Q1 2020 in Review

1834 Investment Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2020, closing a stake of 700 shares — an estimated $6K sold.

1834 Investment Advisors first reported a position in SGMO in Q4 2019 and held it in 1 quarter. The position peaked at $6K in Q4 2019. 190 funds tracked by Wall St. Rank hold SGMO as of Q1 2020.

  • 1834 Investment Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2020 after selling out during the quarter.
  • 1834 Investment Advisors sold 700 SANGAMO THERAPEUTICS INC shares in Q1 2020, an estimated $6K.
  • 1834 Investment Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q4 2019 and held it in 1 quarter.
  • 1834 Investment Advisors's SANGAMO THERAPEUTICS INC position peaked at $6K in Q4 2019.
  • 190 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2020.

Based on 1834 Investment Advisors's 13F filing for Q1 2020, filed 15 May 2020.